- Home
- BRY vs DBVT Comparison
BRY vs DBVT Comparison
Compare BRY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- DBVT
- Stock Information
- Founded
- BRY 1909
- DBVT 2002
- Country
- BRY United States
- DBVT France
- Employees
- BRY N/A
- DBVT N/A
- Industry
- BRY Oil & Gas Production
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRY Energy
- DBVT Health Care
- Exchange
- BRY Nasdaq
- DBVT Nasdaq
- Market Cap
- BRY 249.1M
- DBVT 273.6M
- IPO Year
- BRY N/A
- DBVT N/A
- Fundamental
- Price
- BRY $3.21
- DBVT $8.97
- Analyst Decision
- BRY Buy
- DBVT Buy
- Analyst Count
- BRY 2
- DBVT 4
- Target Price
- BRY $4.00
- DBVT $14.81
- AVG Volume (30 Days)
- BRY 791.8K
- DBVT 33.5K
- Earning Date
- BRY 11-06-2025
- DBVT 11-05-2025
- Dividend Yield
- BRY 3.74%
- DBVT N/A
- EPS Growth
- BRY N/A
- DBVT N/A
- EPS
- BRY 0.07
- DBVT N/A
- Revenue
- BRY $701,914,000.00
- DBVT $3,800,000.00
- Revenue This Year
- BRY N/A
- DBVT $1,743.46
- Revenue Next Year
- BRY $1.15
- DBVT $1,045.66
- P/E Ratio
- BRY $49.27
- DBVT N/A
- Revenue Growth
- BRY N/A
- DBVT N/A
- 52 Week Low
- BRY $2.11
- DBVT $2.21
- 52 Week High
- BRY $5.90
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- BRY 56.62
- DBVT 39.67
- Support Level
- BRY $3.11
- DBVT $9.11
- Resistance Level
- BRY $3.38
- DBVT $10.34
- Average True Range (ATR)
- BRY 0.13
- DBVT 0.52
- MACD
- BRY 0.03
- DBVT -0.08
- Stochastic Oscillator
- BRY 72.58
- DBVT 10.77
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.